Company intelligence / Profile preview

Proligo

Boulder, Colorado, USA

Ownership: Private
Development stage: Other

Overview

Proligo was a prominent global supplier of nucleic acid chemistry products and custom oligonucleotide synthesis services. The company specialized in the production of high-quality phosphoramidites, which are essential building blocks for DNA and RNA synthesis. Proligo was particularly recognized for its expertise in RNA synthesis, supporting the emerging field of RNA interference (RNAi) research during the early 2000s. Following its acquisition by Sigma-Aldrich in 2005, its operations were integrated into Sigma-Aldrich's genomics business. The company's legacy and technologies continue to exist as part of the life science portfolio of Merck KGaA.

Modalities: Synthetic oligonucleotideRNA therapy
Industry: Chemicals & Materials

Partnerships

Dharmacon

Beyond the preview

Go deeper on Proligo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proligo.

Explore the full profile